
Active Biotech Q1 2023 - New Results from naptumomab

Redeye comments on Active Biotech's Q1 report. After the end of Q1, results from naptumomab's phase I /IIa study with durvalumab were published which we discuss.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Active Biotech Q1 2023 - New Results from naptumomab